<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02435173</url>
  </required_header>
  <id_info>
    <org_study_id>CCDZ173X2201</org_study_id>
    <secondary_id>2014-003876-22</secondary_id>
    <nct_id>NCT02435173</nct_id>
  </id_info>
  <brief_title>Study of Efficacy of CDZ173 in Patients With APDS/PASLI</brief_title>
  <official_title>An Open-label, Non-randomized, Within-patient Dose-finding Study Followed by a Randomized, Subject, Investigator and Sponsor-blinded Placebo Controlled Study to Assess the Efficacy and Safety of CDZ173 in Patients With APDS/PASLI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to explore CDZ173, a selective PI3Kδ inhibitor, in patients with&#xD;
      genetically activated PI3Kδ, i.e., patients with Activated phosphoinositide 3-kinase delta&#xD;
      syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and&#xD;
      immunodeficiency (APDS/PASLI). The study consists of two parts: Part I is the open label part&#xD;
      designed to establish the safety and pharmacokinetics of CDZ173 in the target population, as&#xD;
      well as to select the optimal dose to be tested in part II. Part II is designed to assess&#xD;
      efficacy and safety of CDZ173 in this population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to explore CDZ173, a selective PI3Kδ inhibitor, in patients with&#xD;
      genetically activated PI3Kδ, i.e., patients with Activated phosphoinositide 3-kinase delta&#xD;
      syndrome/ p110δ-activating mutation causing senescent T cells, lymphadenopathy and&#xD;
      immunodeficiency (APDS/PASLI). The study consists of two parts: Part I is the open label part&#xD;
      designed to establish the safety and pharmacokinetics of CDZ173 in the target population, as&#xD;
      well as to select the optimal dose to be tested in part II. Part II is designed to assess&#xD;
      efficacy and safety of CDZ173 in this population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 24, 2015</start_date>
  <completion_date type="Actual">August 16, 2021</completion_date>
  <primary_completion_date type="Actual">August 16, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part I of the study was a non-randomized, open-label, within-patient up-titration study.&#xD;
Part II is a randomized, subject, investigator and sponsor-blinded, placebo-controlled, fixed dose study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Part I was a non-randomized, open-label study Part II is a randomized subject, investigator and sponsor-blinded, placebo controlled study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part I: Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>From the start of treatment to 30 days after end of treatment, assessed up to maximum duration of 16 weeks</time_frame>
    <description>Part I: Number of participants with AEs and SAEs, including significant changes from baseline in physical findings, vital signs, electrocardiograms and laboratory values qualifying and reported as AEs. The number of participants in each category is reported in the table.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part I: Single and multiple dose concentrations of CDZ173</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part I: To assess the dose-PD and PK/PD relationship of CDZ173 in patients with APDS/PASLI for dose selection in Part II</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part I: pAkt inhibition in unstimulated and stimulated whole blood</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part I: To assess the dose-PD and PK/PD relationship of CDZ173 in patients with APDS/PASLI for dose selection in Part II</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: Change from baseline in the log10 transformed sum of product of diameters (SPD) in the index lesions selected as per the Cheson methodology from MRI/CT imaging</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part II: To assess the clinical efficacy of CDZ173 in patients with APDS/PASLI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part II: Change from baseline in percentage of naïve B cells out of total B cells</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part II: To assess the clinical efficacy of CDZ173 in patients with APDS/PASLI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part I &amp; II: AUClast</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part I &amp; II: To assess the pharmacokinetics of CDZ173 in patients with APDS/PASLI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I &amp; II: Cmax</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part I &amp; II: To assess the pharmacokinetics of CDZ173 in patients with APDS/PASLI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I &amp; II: To assess the efficacy of CDZ173 to modify health-related quality of life in patients with APDS/PASLI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part I &amp; II: SF-36 (Short Form 36) Survey and WPAI-CIQ (Work Productivity Activity Impairment plus Classroom Impairment Questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I &amp; II: SF-36 (Short Form 36) Survey</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part I &amp; II: To assess the efficacy of CDZ173 to modify health-related quality of life in patients with APDS/PASLI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I &amp; II: Work Productivity Activity Impairment and Classroom Impairment Questionnaire (WPAI-CQ)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part I &amp; II: To assess the efficacy of CDZ173 to modify health-related quality of life in patients with APDS/PASLI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I &amp; II: Visual analogue scales for Physician's Global Assessment (PGA)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part I &amp; II: To assess the efficacy of CDZ173 by the Physician's Global Assessment (PGA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I &amp; II: Visual analogue scales for Patient's Global Assessment (PtGA)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part I &amp; II: To assess the efficacy of CDZ173 by the Patient's Global Assessment (PtGA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I &amp; II: C reactive protein (CRP)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part I &amp; II: To assess biomarkers reflecting the efficacy of CDZ173 to reduce systemic inflammatory components of the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part I &amp; II: Lactate dehydrogenase (LDH)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part I &amp; II: To assess biomarkers reflecting the efficacy of CDZ173 to reduce systemic inflammatory components of the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: beta2 microglobulin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part II: To assess biomarkers reflecting the efficacy of CDZ173 to reduce systemic inflammatory components of the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: ferritin</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part II: To assess biomarkers reflecting the efficacy of CDZ173 to reduce systemic inflammatory components of the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: fibrinogen</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part II: To assess biomarkers reflecting the efficacy of CDZ173 to reduce systemic inflammatory components of the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: Erythrocyte sedimentation rate (ESR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Part II: To assess biomarkers reflecting the efficacy of CDZ173 to reduce systemic inflammatory components of the disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part II: To assess the effect of CDZ173 on lymphadenopathy(non-index lesions and spleen)</measure>
    <time_frame>12 weeks</time_frame>
    <description>MRI/CT imaging - e.g. 3D volume of index and measurable non-index lesions selected as per the Cheson methodology, and 3D volume and bi-dimensional size of the spleen</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Common Variable Immunodeficiency (CVID), APDS / PASLI</condition>
  <arm_group>
    <arm_group_label>Part I: CDZ173</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part I was with-in patient dose escalation with CDZ173 10, 30 and 70 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part II is randomized placebo-controlled with CDZ173 70 mg bid and matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: CDZ173</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part II is randomized placebo-controlled with CDZ173 70 mg bid and matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDZ173</intervention_name>
    <description>Part I: 10, 30 and 70 mg bid Part II: 70 mg bid</description>
    <arm_group_label>Part I: CDZ173</arm_group_label>
    <arm_group_label>Part II: CDZ173</arm_group_label>
    <other_name>Leniolisib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 70 mg bid</description>
    <arm_group_label>Part II: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have a documented APDS/PASLI-associated genetic PI3K delta mutation&#xD;
&#xD;
          -  In Part I and Part II, patients must have nodal and/or extranodal lymphoproliferation,&#xD;
             and clinical findings and manifestations compatible with APDS/PASLI such as a history&#xD;
             of repeated oto-sino-pulmonary infections and/or organ dysfunction (e.g., lung,&#xD;
             liver). Additionally, in part II, patients must have at least one measurable nodal&#xD;
             lesion on a CT or MRI scan.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Any medically significant disease or condition that is unrelated to APDS/PASLI&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koneti V Rao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health (NIH)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Virgil Dalm, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna Šedivá, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Motol University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute of Health NIH</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20814</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minsk</city>
        <zip>223053</zip>
        <country>Belarus</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prague 5</city>
        <zip>150 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117198</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>France</country>
  </removed_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 24, 2015</study_first_submitted>
  <study_first_submitted_qc>April 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2015</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>APDS</keyword>
  <keyword>PASLI</keyword>
  <keyword>PI3Kdelta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Common Variable Immunodeficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

